Company intelligence / Profile preview

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd.

Jiangsu Sheng, China

Ownership: Private
Development stage: Other

Overview

The company has multiple clinical-stage programs. FH-2001 is in Phase 2 for Advanced Malignant Solid Neoplasm, XS-02 is in Phase 1/2 for Advanced Malignant Solid Neoplasm, XS-04 is in Phase 1 for Diffuse Large B-Cell Lymphoma, and XS-03 is in Phase 1 for Colorectal Cancer. Recently received approval for clinical trials of XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for metastatic colorectal cancer with RAS mutations.[1][3]

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

XS-04

Beyond the preview

Go deeper on Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd..